{"id":"NCT05364671","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients","officialTitle":"Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-29","primaryCompletion":"2023-08-18","completion":"2023-08-18","firstPosted":"2022-05-06","resultsPosted":"2025-01-06","lastUpdate":"2025-01-06"},"enrollment":771,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Coronavirus Disease 2019 (COVID-19)"],"interventions":[{"type":"DRUG","name":"Raphamin","otherNames":["MMH-407"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Raphamin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.","primaryOutcome":{"measure":"Number of Participants With COVID-19 Progression to a More Severe Form","timeFrame":"28 days","effectByArm":[{"arm":"Raphamin","deltaMin":59,"sd":null},{"arm":"Placebo","deltaMin":89,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0088"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":382},"commonTop":["Increased transaminases","Nausea","Increased blood pressure","Increased C-reactive protein","Itching, cutaneous"]}}